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Abstract
Purpose: Positron emission tomography using 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT) has
been suggested as a means for monitoring response to chemotherapy. The aim of this study
was to evaluate the validity of simplified uptake measures for assessing response to
chemotherapy using [18F]FLT in locally advanced breast cancer (LABC).
Procedures: Fifteen LABC patients underwent dynamic [18F]FLT scans both prior to and after
the first cycle of chemotherapy with fluorouracil, epirubicin or doxorubicin, and cyclophospha-
mide. The net uptake rate constant of [18F]FLT, Ki, determined by non-linear regression (NLR) of
an irreversible two-tissue compartment model was used as the gold standard. In addition to
Patlak graphical analysis, standardised uptake values (SUV) and tumour-to-whole blood ratio (TBR)
were used for analysing [18F]FLT data. Correlations and relationships between simplified uptake
measures and NLR before and after chemotherapy were assessed using regression analysis.
Results: No significant differences in both pre- and post-chemotherapy relationships between
any of the simplified uptake measures and NLR were found. However, changes in SUV between
baseline and post-therapy scans showed a significant negative bias and slope less than one,
while TBR did not.
Conclusions: In LABC, TBR instead of SUV may be preferred for monitoring response to
chemotherapy with [18F]FLT.
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Introduction
T he positron emission tomography (PET) tracer 3′-deoxy-3′-[18F]ﬂuorothymidine ([18F]FLT) [1], a thy-
midine analogue that is a marker of tumour proliferation, is a
promising tracer for monitoring treatment response and
predicting outcome. It has been shown that [18F]FLT uptake
strongly correlates with the proliferation index as measured by
Ki-67 immunohistochemistry in lung and breast tumours [2], as
well as with thymidine kinase-1 expression in lung tumours [3].
The gold standard for analysing tracer uptake in tissue
is by non-linear regression (NLR) of operational equationsCorrespondence to: Mark Lubberink; e-mail: mark.lubberink@radiol.uu.se
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based on compartmental models. In case of [18F]FLT, a
two-tissue compartment model is used and, in general, it
is assumed that phosphorylated tracer is irreversibly
trapped [4–10]. When scan durations longer than 60 min
are used, dephosphorylation can no longer be neglected
and a two-tissue reversible compartment model may be
preferred [8]. Alternatively, a basis function approach, not
requiring prior assumptions about the exact underlying
compartment model, can be used [11]. A good correlation
between net uptake rate Ki of [
18F]FLT and Ki-67
immunohistochemistry has been shown [2, 11]. Although
full kinetic analysis is, in principle, the most accurate
method for determining net uptake of [18F]FLT, it is
also relatively complex, at the expense of clinical
applicability.
Two simpliﬁed methods often are used to (semi-)
quantitatively assess [18F]FLT uptake: graphical (Patlak)
analysis [12] and standardised uptake values (SUV). Patlak
analysis assumes irreversible trapping in tissue, and its
accuracy thus depends on the assumption that no signiﬁcant
dephosphorylation occurs within the time course of the
study. Both NLR and Patlak measure net uptake of [18F]
FLT, taking into account the concentration of tracer in
plasma during the course of the study. Only NLR, however,
allows for measurements of individual rate constants
between compartments and for an implicit correction for
blood volume in the tissue of interest. SUV is the ratio of
tissue concentration and injected activity at a certain time
after administration of the tracer. It does not take tracer
kinetics into account but has the advantage that it is a single-
scan procedure that does not require plasma data. Previous
studies have shown a good correlation between [18F]FLT
SUV and net uptake calculated using Patlak analysis in for
example untreated lung cancer and breast cancer patients, as
well as in patients with recurrent glioma [8, 11, 13]. Kenny
and co-workers [14] showed that both SUV and Patlak-
derived Ki predicted response to chemotherapy for breast
cancer after the ﬁrst cycle of chemotherapy with good
reproducibility. They did not speciﬁcally address the
relationship of changes in SUV with those in NLR-derived
Ki.
For simpliﬁed uptake measures to be valid for
monitoring response or predicting outcome, their relation-
ship with the more accurate outcome measures of full
kinetic analysis must be similar before and after therapy.
Chemotherapy, however, might alter the correlations
between NLR, Patlak and SUV, as has previously been
shown for 2-deoxy-2-[18F]ﬂuoro-D-glucose [15]. This
could be due to changes in tumour blood ﬂow, blood
volume or plasma clearance of the tracer. The changes are
accounted for in full kinetic analysis (NLR), but not in
the use of SUV. In those cases, the use of SUV can lead
to erroneous conclusions on response or progressive
disease. Therefore, the aim of the present study was to validate
simpliﬁed [18F]FLT uptake measures for monitoring response
to chemotherapy in locally advanced breast cancer (LABC) by




Data were used from 15 LABC patients participating in an ongoing
response monitoring study, the protocol of which was approved by
the medical ethics review committee of the VU university medical
centre and for which all patients had given written informed
consent. Patients underwent an [18F]FLT scan shortly before the
start of chemotherapy and again 3 weeks later, shortly before the
second cycle of chemotherapy in case of traditional, three-weekly
schemes (n=12) or before the fourth cycle in case of weekly
schemes (n=3). The median delay between baseline PET scan and
start of chemotherapy was 1 day (range 0–9 days). Chemotherapy
consisted of ﬂuorouracil and cyclophosphamide combined with
either epirubicin or doxorubicin.
PET Acquisition Protocol
PET scans were performed using an ECAT EXACT HR+
scanner (Siemens/CTI, Knoxville, TN). First, a 10-min trans-
mission scan over the tumour area was performed using three
retractable 68Ge/68Ga line sources. A 60-min dynamic emission
scan (6×5, 6×10, 3×20, 5×30, 5×60, 8×150, 6×300 s) was
subsequently performed in 2D acquisition mode after bolus
injection of ~370 MBq [18F]FLT.
During the [18F]FLT scan, six venous samples were drawn at set
times, both for immediate measurement of whole blood and plasma
radioactivity concentrations and for measurement of metabolite
fractions using solid-phase extraction chromatography to separate
FLT from FLT-glucuronide. For this procedure 0.3 ml plasma was
dissolved in 2 ml water. This solution was brought onto a SepPak®
Vac 6-cc (1 g) C18 cartridge (Waters Corporation, Milford, MA).
The eluate was collected, after which the cartridge was rinsed with
5 ml water to collect polar metabolites, primarily being [18F]FLT-
glucuronide. The cartridge was then rinsed with 5 ml ethanol 96%
to collect the parent compound. All fractions and the cartridge were
counted using a Wallac 1480 Wizard well counter (Perkin-Elmer
Life Science, Zaventem, Belgium), and the percentage parent
within each plasma sample calculated.
Image Reconstruction and Processing
Scan data were normalised and corrected for dead time, decay, scattered
radiation, random coincidences and photon attenuation, and were
reconstructed using ﬁltered back projection (FBP) with a Hanning ﬁlter
(cut-off 0.5 cycles/pixel). This resulted in a transaxial spatial resolution
of approximately 7 mm full width at half maximum (FWHM). For
region of interest (ROI) deﬁnition, the last three frames (i.e., 45–60 min
p.i.) were summed and reconstructed using attenuation-weighted
ordered subset expectation maximisation with two iterations and 16
subsets, followed by post smoothing using a 5-mm FWHM Gaussian
ﬁlter to obtain the same resolution as the dynamic images reconstructed
with FBP. Volumes of interest (VOIs) were deﬁned semi-automatically
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over the tumour by applying a threshold of 70% of the maximum pixel
value within the lesion. Tumour VOIs were transferred to the FBP-
reconstructed dynamic data to create time–activity curves (TAC). In
patients with multiple breast cancer lesions, the primary tumour was
analysed. Arterial TACs were measured using 1.5-cm-diameter circular
ROIs manually deﬁned over the aortic arch, ascending aorta, left atrium
and left ventricle in the frame of the FBP-reconstructed dynamic image
in which the injected bolus was best seen passing through these
structures [16, 17]. These ROIs were then projected onto all frames.
Absolute radioactivity concentration in the arterial TACs was veriﬁed
using the radioactivity concentrations measured in the blood samples.
Arterial TACs were then converted to image-derived input functions by
ﬁrst multiplying them with a single exponential ﬁt to plasma to whole
blood ratio data and subsequently with a sigmoid function ﬁt [18] to
parent fraction data.
Data Analysis
Data were analysed using in-house developed software written in
Matlab (Natick, MA). The following analytical methods were
applied:
1. Net uptake rate (Ki) was determined by NLR, using
reversible or irreversible two-tissue compartment models
with four (NLR4k) or three (NLR3k; k4=0) parameters,
respectively, and a blood volume parameter. The presence
of a fourth rate constant k4 and the need to include this in
the NLR model were assessed by comparing residual sum
of squares of ﬁts with and without a k4 parameter using
the Akaike and Schwarz criteria [19].
2. Patlak analysis, giving net uptake rate Ki, using the 10–
60-min post-injection data,
3. SUV for the 50–60-min interval normalised to body
weight, and
4. Tumour-to-whole blood ratio (TBR), i.e., tumour SUV
normalised to whole blood SUV at 50–60 min p.i.,
obtained from the arterial TAC.
The metabolite-corrected plasma time–activity curve was used
as input function in both NLR and Patlak analyses. Correlation and
agreement between all measures of [18F]FLT uptake and NLR were
assessed using orthogonal regression, Spearman’s correlation
coefﬁcient and intraclass correlation coefﬁcients (ICC). Relative
and absolute changes in Patlak-derived Ki, SUV and TBR were
compared with NLR3k-derived Ki using orthogonal regression.
Conﬁdence intervals of regression parameters were estimated by
bootstrapping using 1,000 resamples obtained by random sampling
with replacement from the measured data.
Results
Patients and Scans
For one patient, [18F]FLT scans were excluded because no
good ﬁt could be obtained for the second scan, probably due to
patient movement. The mean fraction of parent [18F]FLT at
60 min p.i. was 79% and 80% for baseline and post-
chemotherapy measurements, respectively, with a range of
71–85% at baseline and of 74–84% after chemotherapy. There
were no signiﬁcant differences between pre- and post-therapy
values (p=0.68). Mean whole blood and plasma SUV at
60 min p.i. were signiﬁcantly lower for post-chemotherapy
[18F]FLT scans than for baseline scans (whole blood: mean
(SD) SUV 0.57 (0.09) versus 0.61 (0.09), p=0.05, and plasma:
mean (SD) SUV 0.66 (0.12) versus 0.72 (0.10), p=0.02).
Data Analysis
The NLR3kmodel provided better ﬁts than the NLR4kmodel in
17 out of 28 (61%) [18F]FLT scans, respectively, according to
the Akaike criterion, with similar results for the Schwarz
criterion. Based on these criteria, a fourth rate constant could
Fig. 1. Correlation of Patlak-derived Ki versus NLR3k-derived
Ki at baseline (closed circles, solid line) and post-chemotherapy
(open circles, dashed line). The lines are orthogonal regressions.
Table 1. [18F]FLT simpliﬁed measures versus NLR
NLR3k Ki Patlak Ki NLR3k Ki SUV NLR3k Ki TBR
Spearman’s rho 0.98 0.96 0.96
ICC 0.98 n.a. n.a.
Slope baseline (CI) 1.01 (0.90–1.13) 101 (90–113) 140 (119–164)
Intercept baseline (CI) −0.003 (−0.005 to 0.000) 0.34 (−0.00 to 0.75) 0.16 (−0.42 to 0.64)
Slope post-therapy (CI) 1.00 (0.86–1.17) 108 (95–142) 147 (136–179)
Intercept post-therapy (CI) −0.002 (−0.006 to 0.001) 0.09 (−0.49 to 0.37) 0.15 (−0.41 to 0.41)
n.a. not available
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not be reliably identiﬁed and therefore NLR3k was used in the
remainder of this study.
Figure 1 shows net uptake rates of [18F]FLT as measured
using Patlak analysis versus those measured using NLR3k.
Corresponding correlation parameters are shown in Table 1.
No signiﬁcant differences between baseline and post-
chemotherapy slopes of the relationships between Patlak
and NLR were found.
Figure 2 shows correlations between SUV, TBR and
NLR3k-derived Ki. Corresponding relationships are summa-
rized in Table 1. Correlation and agreement of SUV and
TBR with NLR3k-derived Ki were similar. A non-signiﬁcant
post-chemotherapy increase in slope between NLR3k-derived
Ki and SUV of about 7% was found.
Figures 3 and 4 and Table 2 show relative changes in
simpliﬁed uptake measures versus those obtained for NLR3k-
derived Ki after chemotherapy. The slope of ΔSUV versus ΔKi
was signiﬁcantly smaller than one (0.69, conﬁdence interval CI
0.57 to 0.88), and a signiﬁcant negative bias of −0.12 (CI −0.16
to −0.05) inΔSUVwas seen. Absolute changes in SUV showed
a signiﬁcant bias of −0.20 (CI −0.37 to −0.03) as well. The slope
of ΔTBR versus ΔKi was not signiﬁcantly different from one
(0.82, CI 0.56–1.13), and bias was smaller and non-signiﬁcant
(−0.03, CI −0.12 to 0.09) as well, although the correlation
between ΔTBR and ΔKi (rho=0.93) was slightly lower than
between ΔSUV and ΔKi (rho=0.96).
Discussion
In the present study, the use of simpliﬁed uptake measures
for measuring breast cancer treatment response using [18F]
FLT was compared to non-linear regression, i.e., to full tracer
kinetic analysis. Although previous studies have shown a good
correlation between [18F]FLT SUV and net uptake calculated
using NLR and Patlak analysis in untreated lung cancer and
breast cancer patients [8, 11], the present study also addresses
correlation between responses as measured using NLR and
simpliﬁed methods. Therapy-induced changes in SUV were
negatively biased compared to changes in NLR-derived Ki,
with no change in Ki corresponding to an 11% decrease in
SUV. TBR did not suffer from this bias.
As [18F]FLT uptake is primarily mediated by TK-1
activity, it can be argued that k3 may be a more accurate
predictor of tumour proliferation than Ki, which is also
dependent on other factors (i.e., blood ﬂow). Unfortunately,
however, the accuracy of NLR in determining micro
parameters such as k3 is far lower than that of Ki [20], with
more than half of the individual k3 measurements showing
standard errors of 20% or more. Since previous studies have
shown good correlation between NLR-derived Ki and the
proliferation marker Ki-67, as determined by immunohisto-
chemistry [2], this Ki was chosen as the standard in the
present study. The use of a fourth parameter has been
suggested for [18F]FLT based on the potentially reversible
behaviour of the tracer [8]. However, apart from the three-
parameter model being preferred by the Akaike and
Schwartz criteria in the present study, Ki values derived
from the reversible model showed a much higher uncertainty
than those determined using the irreversible model. In
Fig. 2. Correlation of a SUV and b TBR versus NLR3k-derived Ki, at baseline (closed circles, solid line) and post-chemotherapy
(open circles, dashed line). The lines are orthogonal regressions.
Fig. 3. Correlation between relative change in Patlak Ki and
NLR3k Ki. The solid line is an orthogonal regression; the
dashed lines show the 95% confidence interval of the
regression line.
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addition, Patlak plots of the 10–60-min interval were linear,
which suggests that in the present study no dephosphoryla-
tion of [18F]FLT occurs during the ﬁrst 60-min p.i.
As shown previously [5, 10, 21], results of the Patlak
analysis correlated very well with NLR3k. In addition, no
differences in pre- and post-chemotherapy relationships with
NLR3k were found, and there was a high correlation between
changes in the Patlak and NLR3k-derived Ki values. However,
as Patlak analysis still requires dynamic scanning and a plasma
input function, it is generally not considered to be a measure
that can be used in routine clinical practice.
The fact that a signiﬁcant negative bias in ΔSUV compared
to ΔKi was found for [
18F]FLT suggests that less tracer was
available for uptake into malignant tissue, possibly because of
higher post-chemotherapy uptake in other (normal) tissues as a
result of the treatment. This is conﬁrmed by a signiﬁcantly
lower plasma radioactivity concentration at 60 min p.i. A
reduction in tumour perfusion would cause a decrease in both
SUV and Ki and can therefore not explain the preferential
reduction of SUV.
Figure 4 suggests that SUV is considerably less sensitive
than NLR3k in detecting therapy-induced changes in tumour
metabolism, with a slope of ΔSUV versus ΔKi of about 0.7.
However, previous studies have shown that test–retest
variability of [18F]FLT SUV is considerably better than that
of Ki [14, 20]. In general, an approximately 30% larger
change in Ki than in SUV had to be found for it to be
considered as a response [20]. The lower sensitivity but
better reproducibility of SUV suggests that SUV and Ki have
comparable sensitivity in response monitoring, with ΔSUV
showing a negative bias.
Potentially, TBR, the change of which does not show a
negative bias relative to ΔKi, could be a better measure for
treatment response than SUV, provided its test–retest
variability is comparable to or better than that of SUV. This
needs to be assessed in future studies. The clinical relevance
of the differences between SUV and TBR, as found in the
present work, will be assessed in a clinical study. In the
present work, TBR was calculated using the mean value of
the arterial TAC between 50 and 60 min. In 11 out of 14
patients, a venous whole blood sample taken between 55 and
60 min p.i. was available. For these 11 patients, correlation
and agreement between ΔTBR and ΔKi were better when
TBR was based on blood sample data than on image-derived
blood data (Pearson’s r2 0.92 versus 0.81; Spearman’s rho
0.95 for both cases), whilst the relation between ΔSUV or
image-based ΔTBR and ΔKi was similar for these 11
patients as for the complete group of 14 patients (Fig. 5).
This suggests that, probably because of the noisy nature of
the arterial TAC at 50–60 min p.i., use of a blood sample
might produce more robust TBR values. Although TBR, as
opposed to SUV, does take post-therapy changes in whole
Fig. 4. Correlation between relative change in a SUV and b TBR versus NLR3k Ki. The solid lines are orthogonal regressions;
the dashed lines show the 95% confidence intervals of the regression lines.
Table 2. [18F]FLT: relative change in simpliﬁed measures versus NLR



















Fig. 5. Correlation between relative change in TBR versus
NLR3k Ki, using a blood sample at 55–60 min p.i. for
calculation of TBR instead of an ascending aorta VOI. The
solid line is an orthogonal regression; the dashed lines show
the 95% confidence interval of the regression line.
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blood clearance into account, it cannot account for therapy-
induced changes in metabolism. If major changes in
metabolism are observed for a certain type of chemotherapy,
the validity of TBR has to be addressed by comparison to
full kinetic modelling using NLR with a metabolite-
corrected plasma input function, and full kinetic modelling
may be preferable.
Conclusion
For [18F]FLT, change in SUV was negatively biased compared
to change in NLR3k-derived Ki, with no change in Ki
corresponding to a signiﬁcant decrease in SUV. Use of TBR
did not show this bias and has a similar correlation to NLR3k-
derived Ki. Therefore, tumour-to-whole blood ratio may be
preferred to SUV as a simpliﬁed measure for monitoring
response to chemotherapy in LABC when using [18F]FLT.
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